Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
76.79
-0.08 (-0.10%)
At close: Aug 12, 2026, 4:00 PM EDT
76.78
-0.01 (-0.01%)
After-hours: Aug 12, 2026, 4:47 PM EDT
Company Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes.
Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Paul A. Wagner |
Contact Details
Address: 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States | |
| Phone | 310 618 6994 |
| Website | fortebiorx.com |
Stock Details
| Ticker Symbol | FBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1419041 |
| CUSIP Number | 34962G208 |
| ISIN Number | US34962G2084 |
| Employer ID | 26-1243872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President and Chairman |
| Dr. Barbara K. Finck M.D. | Senior Medical Clinician and Director |
| Christopher Roenfeldt | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2026 | SCHEDULE 13G/A | Filing |
| Aug 11, 2026 | SCHEDULE 13G | Filing |
| Aug 7, 2026 | SCHEDULE 13G/A | Filing |
| Aug 7, 2026 | SCHEDULE 13G/A | Filing |
| Aug 6, 2026 | SC TO-T/A | Filing |
| Aug 6, 2026 | SC 14D9 | Filing |
| Aug 6, 2026 | SC TO-T | Filing |
| Jul 28, 2026 | SC TO-C | Filing |
| Jul 28, 2026 | SCHEDULE 13G | Filing |
| Jul 27, 2026 | SC TO-C | Filing |